Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community (Study #3; Aim 2 Injectable CAB/RPV Pilot)
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Cabotegravir+rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 29 Nov 2024 New trial record